top of page

Newsroom Latest News

Newsroom: Latest News

Media Inquiries

Igyxos Announces Positive Results from Single Ascending Dose Phase I Study of IGX12, a First-in-class Therapeutic Monoclonal Antibody Enhancing FSH Activity

MAR11

2025

Igyxos Biotherapeutics Strengthens Its Leadership Team with the Appointments of Florent Ferré as CEO and Dr. Elke Bestel as Chief Medical Officer

DEC19

2024

Meet Igyxos at ESHRE2024 in Amsterdam !
Igyxos will present two posters at ESHRE2024 in Amsterdam (7-10 july 2024).

JUN28

2024

Studies Suggest Sperm Counts Have Declined 50% in the Last 50 Years; New Innovation May Help Address Male Infertility

JUN04

2024

IGYXOS to Attend BIO International Convention 2024

MAY29

2024

IGYXOS Initiates Phase 1 Clinical Trials for IGX12: A Breakthrough Treatment for Infertility

NOV16

2023

4

Igyxos selected for the French Tech 120 (FT120) program for the third consecutive year

APR25

2022

3

Igyxos pursues its development and appoints Thierry Ziegler as CMC Chief Operating Officer

MAR15

2021

2

Igyxos and Selexis enter service agreement to advance Igyxos’ first-in-class monoclonal antibody for the treatment of human infertility

SEP02

2020

1

Igyxos raises €7.5 million to finance the preclinical and clinical development of its drug candidate First-In-Class in the treatment of human infertility

MAR21

2019

bottom of page